• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥马珠单抗治疗失败,酮替芬治疗振动性血管性水肿成功控制。

Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema.

机构信息

Department of Prevention and Sports Medicine, Technische Universität München, Munich, Germany.

出版信息

Clin Exp Dermatol. 2013 Mar;38(2):151-3. doi: 10.1111/j.1365-2230.2012.04430.x. Epub 2012 Jun 25.

DOI:10.1111/j.1365-2230.2012.04430.x
PMID:22731986
Abstract

Vibratory angio-oedema is a rare form of physical urticaria characterized by pruriginous weals and angio-oedema at the site of exposure to vibration. Severe treatment-resistant disease can occur, and is associated with significant disability. Therapy with omalizumab, a monoclonal IgG anti-IgE antibody, has been shown to be successful in several types of physical urticaria. We report a patient with vibratory angio-oedema for whom all standard treatments for urticaria, including omalizumab, failed to show a clinical benefit. Finally, ketotifen was tried, and unexpectedly reduced symptoms significantly. Ketotifen may thus represent a therapeutic option in patients with treatment-resistant vibratory angio-oedema.

摘要

振动性血管性水肿是一种罕见的物理性荨麻疹,其特征是在接触振动的部位出现瘙痒性风团和血管性水肿。严重的、治疗抵抗的疾病可能会发生,并与显著的残疾相关。奥马珠单抗是一种单克隆 IgG 抗 IgE 抗体,已被证明对几种类型的物理性荨麻疹有效。我们报告了一例振动性血管性水肿患者,所有标准的荨麻疹治疗方法,包括奥马珠单抗,均未显示出临床获益。最后,尝试了酮替芬,出乎意料地显著减轻了症状。因此,酮替芬可能是治疗抵抗性振动性血管性水肿患者的一种治疗选择。

相似文献

1
Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema.奥马珠单抗治疗失败,酮替芬治疗振动性血管性水肿成功控制。
Clin Exp Dermatol. 2013 Mar;38(2):151-3. doi: 10.1111/j.1365-2230.2012.04430.x. Epub 2012 Jun 25.
2
A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema.对奥马珠单抗作为慢性难治性荨麻疹/血管性水肿治疗选择的批判性评价。
Ann Allergy Asthma Immunol. 2014 Apr;112(4):276-9. doi: 10.1016/j.anai.2014.01.019. Epub 2014 Feb 28.
3
Omalizumab for the treatment of chronic urticaria.奥马珠单抗治疗慢性荨麻疹。
Expert Rev Clin Immunol. 2015 Feb;11(2):171-80. doi: 10.1586/1744666X.2015.993971. Epub 2015 Jan 7.
4
A patient with steroids and antihistaminic drug allergy and newly occurred chronic urticaria angioedema: what about omalizumab?一位对类固醇和抗组胺药过敏且新出现慢性荨麻疹血管性水肿的患者:那奥马珠单抗呢?
Hum Exp Toxicol. 2014 Aug;33(8):882-5. doi: 10.1177/0960327113510539. Epub 2013 Nov 7.
5
Treatment of chronic autoimmune urticaria with omalizumab.用奥马珠单抗治疗慢性自身免疫性荨麻疹。
J Allergy Clin Immunol. 2008 Sep;122(3):569-73. doi: 10.1016/j.jaci.2008.07.006.
6
Update and insights into treatment options for chronic spontaneous urticaria.慢性自发性荨麻疹治疗选择的更新与见解。
Expert Rev Clin Immunol. 2014 Mar;10(3):397-403. doi: 10.1586/1744666X.2014.892416.
7
The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology.抗 IgE 抗体奥马珠单抗作为一种探针来研究 IgE 在病理学中的作用。
Panminerva Med. 2012 Dec;54(4):305-12.
8
Positive response to omalizumab in patients with acquired idiopathic nonhistaminergic angioedema.奥马珠单抗对获得性特发性非组胺能性血管性水肿患者的阳性反应。
Ann Allergy Asthma Immunol. 2015 May;114(5):418-9.e1. doi: 10.1016/j.anai.2015.02.007. Epub 2015 Mar 4.
9
Extraordinary response to omalizumab in a child with severe chronic urticaria.重度慢性荨麻疹患儿对奥马珠单抗的显著反应。
Eur Ann Allergy Clin Immunol. 2014 Jan;46(1):41-2.
10
Chronic urticaria: omalizumab and review of therapeutic options.慢性荨麻疹:奥马珠单抗及治疗选择综述
J Drugs Dermatol. 2013 Jun 1;12(6):715-6.

引用本文的文献

1
Review of Physical Urticarias and Testing Methods.物理性荨麻疹及其检测方法综述。
Curr Allergy Asthma Rep. 2017 Aug;17(8):51. doi: 10.1007/s11882-017-0722-1.
2
Off-Label Uses of Omalizumab.奥马珠单抗的非标签用途。
Clin Rev Allergy Immunol. 2016 Feb;50(1):84-96. doi: 10.1007/s12016-015-8490-y.